<DOC>
	<DOC>NCT02063555</DOC>
	<brief_summary>This is a Phase 1, randomized, controlled, double-blind, multiple-dose, dose-ranging study of DAR 901, (an inactivated whole cell mycobacterial vaccine) to be conducted in HIV negative and HIV positive adults previously vaccinated with BCG. The goals of the trial are to determine the safety, tolerability, and immunogenicity of multiple doses of the vaccine at different dose levels, ranging from 0.1 to 1 mg.</brief_summary>
	<brief_title>Phase I Trial of DAR-901</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>All subjects: age 1865, prior BCG vaccine (scar) 56 HIV negative subjects: negative ELISA for HIV (48 subjects with negative IGRA, 8 subjects with positive IGRA) 21 HIV positive subjects: positive ELISA for HIV, on ART (13 subjects with negative IGRA, 8 subjects with positive IGRA) pregnancy, positive serology for hepatitis B or C, active tuberculosis immunosuppression, severe medical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>BCG</keyword>
	<keyword>HIV</keyword>
	<keyword>TB Vaccines</keyword>
</DOC>